Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases
- Conditions
- Colorectal Liver Metastases
- Interventions
- Radiation: one time radiationRadiation: No Radiation
- Registration Number
- NCT01191632
- Lead Sponsor
- Heidelberg University
- Brief Summary
The efficiency of T cell based immunotherapies is affected by the insufficient migration and activity of tumor specific effector T cells in the tumor. Aim of this phase I/II clinical trial is to evaluate whether a neoadjuvant, low dose radiotherapy can improve T cell connected anti tumor immune response in colorectal liver metastases.
The primary endpoint is the number of tumor infiltrating T cells. Furthermore the T cell activity in situ, the number of regulatory T cells and the frequency of tumor reactive T cells in the blood and bone marrow will be examined.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
- Ability of subject to understand character and individual consequences of the clinical trial
- Written informed consent (must be available before enrolment in the trial)
- Age ≥ 50 years
- Radiological urgently suspected colorectal liver metastasis
- second malignancy
- Pregnancy and lactation
- no prior liver radiation
- liver metastasis must be resectable
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Radiation 0,5Gy one time radiation Radiation: one time Radiation with an intensity of 0.5 Gy Group A Beginning on a weekday 48 hours before surgery No radiation No Radiation Control group with 0Gy radiation Radiation 2Gy one time radiation Radiation: one time Radiation with an intensity of 2.0 Gy Group B Beginning on a weekday 48 hours before surgery Radiation 5Gy one time radiation Radiation: one time Radiation with an intensity of 5 Gy Group C Beginning on a weekday 48 hours before surgery
- Primary Outcome Measures
Name Time Method Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity 2 years
- Secondary Outcome Measures
Name Time Method To determine the progression-free survival in patients treated with low dose photon beam radiation therapy 2 years • To determine the surgical morbidity in patients undergoing liver resection who received this protocol treatment 2 years • To determine 30-day post-operative mortality after liver resection in patients who received this protocol treatment 2 years • To determine the T-cell activity in the resected liver tissue 2 years To determine local control and recurrence patterns of colorectal liver metastases in a CT 2 years • To determine quality of life according to the EORTC QoL questionnaire after 6 months. 6 months To determine the number of regulatory T-cells in the resected liver tissue 2 years To determine the frequencies of tumor-reactive T-cells in the blood and bone marrow of the patients 2 years To determine quality of life according to the EORTC QoL questionnaire after 12 months. 1 year To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria 2 years
Trial Locations
- Locations (1)
University of Heidelberg
🇩🇪Heidelberg, Germany